3 min read
China’s pharmaceutical market is becoming one of the most attractive destinations for global drug manufacturers, but also one of the most regulated.
In early 2026, China introduced major revisions to the Regulations for the Implementation of the Drug Administration Law, marking one of the most significant Regulatory updates in recent years. At the same time, the National Medical Products Administration (National Medical Products Administration (NMPA)) has continued accelerating drug approvals, with more than 120 approvals reported across multiple therapeutic categories, creating stronger competition among global pharmaceutical companies seeking faster market entry.
For foreign pharmaceutical companies, these two developments signal opportunity but also greater compliance responsibility. One major requirement now becoming increasingly important is having reliable China Local Representation (LR) support.
What Changed in China’s 2026 Drug Administration Law?
China’s State Council officially revised the implementing regulation of the Drug Administration Law in January 2026, with the new rules taking effect on May 15, 2026. The updated regulation introduced sweeping changes across the entire drug lifecycle from R&D and registration to manufacturing and post-market compliance.
Some of the biggest updates include:
1. Stronger Marketing Authorization Holder (MAH) Accountability
The revised law introduces a dedicated chapter for Marketing Authorization Holders (MAHs), making them fully responsible for:
- Product quality
- Pharmacovigilance compliance
- Batch release
- Manufacturing oversight
- Post-market surveillance
This means companies can no longer treat approval as the finish line. Regulatory responsibility continues throughout the product lifecycle.
2. Mandatory Local Entity Support for Overseas Companies
Foreign drug manufacturers must appoint a qualified legal entity in China to handle Regulatory responsibilities.
This local representative may support:
- Regulatory submissions
- Communication with Chinese authorities
- Product maintenance
- Adverse event reporting
- Compliance documentation
- License renewals
Without strong local representation, foreign manufacturers may face delays, compliance gaps, or approval risks.
3. Expanded Data Exclusivity Protection
China is offering stronger incentives for innovation through:
- Up to 6 years of data protection
- Up to 7 years of exclusivity for rare disease drugs
- Additional exclusivity for paediatric medicines
These changes make China increasingly attractive for innovative pharmaceutical companies.
4. Greater Manufacturing Flexibility
The revised framework now allows:
- Contract manufacturing
- Segmented manufacturing
- Multi-site production models
While this improves operational flexibility, it also creates additional compliance responsibilities for manufacturers.
China’s NMPA Approvals Are Rising Rapidly
China is aggressively reducing approval timelines to improve patient access to innovative medicines.
According to recent updates, the revised regulation supports:
- Faster approval pathways
- Priority reviews
- Conditional approvals
- Special approval mechanisms
- Accelerated review for high-value innovations
The country has already seen a sharp rise in approvals in 2026, signaling stronger Regulatory efficiency and increased market opportunities.
For global pharmaceutical companies, this creates urgency:
If competitors are entering China faster, delays in local compliance can directly impact market share.
Why Local Representation Services Are Becoming Critical
Foreign pharmaceutical companies often underestimate China’s local compliance requirements.
A trusted local representative helps companies:
- Navigate Regulatory complexity China’s Regulatory landscape changes quickly. Local experts help interpret evolving rules.
- Manage communication with NMPA Language barriers and procedural misunderstandings can slow approvals.
- Ensure post-approval compliance Registration approval is only one step; ongoing compliance matters just as much.
- Reduce operational risk Missing documentation, reporting obligations, or renewals can lead to penalties.
- Accelerate market entry Strong local Regulatory partners help companies launch faster.
Who Needs China Local Representation?
These services are especially valuable for:
- Global pharmaceutical companies
- Biotech firms entering China
- Generic manufacturers
- Rare disease drug developers
- Paediatric drug innovators
- Companies using contract manufacturing models
Any overseas company without a physical Regulatory infrastructure in China should strongly consider local representation support.
The Future of China Drug Registration
China is clearly shifting toward a faster, innovation-friendly Regulatory environment, but with stricter accountability.
For global pharmaceutical companies, success in China will depend on balancing:
Speed + Compliance + Local Expertise
As NMPA approvals continue rising and regulations become more sophisticated, having the right local partner could determine whether companies scale successfully or face costly delays.
How Freyr Can Help
At Freyr Solutions, we help pharmaceutical companies navigate complex China Regulatory requirements through:
- Local Representation support
- Regulatory submissions
- Registration lifecycle management
- Pharmacovigilance support
- Post-approval compliance
- Market expansion strategies
If you're planning to enter China’s pharmaceutical market, now is the time to strengthen your compliance strategy.
